ZymoGenetics

ZymoGenetics is a biopharmaceutical company with a development pipeline of proteins, antibodies, and antibody-like molecules. Our mission is to create new protein-based drugs that will significantly help patients combat their diseases. We have contributed to the discovery or development of six recombinant protein products, which are now marketed by other companies. Current programs target inflammation and autoimmune diseases, bleeding, cancer, and viral indications. Our first internally developed product, RECOTHROM® Thrombin, Topical (Recombinant), received approval from the U.S. Food and Drug Administration (FDA) on January 17, 2008, as a topical hemostatic agent to control mild to moderate bleeding during surgical procedures and is now commercially available in the United States. We have a robust pipeline of novel therapeutic candidates that we are developing either independently or in collaboration with partners.